Skip to main content

Table 4 Summary of treatment-emergent adverse events that occurred ≥3% in any treatment group

From: Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

  Pateclizumab ADA Placebo
(n = 86) (n = 85) (n = 43)
Pharyngitis 7 (8.1%) 7 (8.2%) 4 (9.3%)
Headache 3 (3.5%) 11 (12.9%) 2 (4.7%)
Urinary tract infection 7 (8.1%) 7 (8.2%) 2 (4.7%)
Hypertension 5 (5.8%) 5 (5.9%) 1 (2.3%)
Nasopharyngitis 4 (4.7%) 4 (4.7%) 3 (7.0%)
Anemia 5 (5.8%) 3 (3.5%) 2 (4.7%)
Diarrhea 2 (2.3%) 5 (5.9%) 3 (7.0%)
Alanine aminotransferase increased 2 (2.3%) 3 (3.5%) 4 (9.3%)
Rheumatoid arthritis 3 (3.5%) 3 (3.5%) 3 (7.0%)
Gastroenteritis 3 (3.5%) 3 (3.5%) 1 (2.3%)
  1. ADA, adalimumab.